221 related articles for article (PubMed ID: 10352282)
1. The tumorigenicity of IL-2 gene-transfected murine M-3D melanoma cells is determined by the magnitude and quality of the host defense reaction: NK cells play a major role.
Schneeberger A; Koszik F; Schmidt W; Kutil R; Stingl G
J Immunol; 1999 Jun; 162(11):6650-7. PubMed ID: 10352282
[TBL] [Abstract][Full Text] [Related]
2. Elicitation of a systemic and protective anti-melanoma immune response by an IL-2-based vaccine. Assessment of critical cellular and molecular parameters.
Zatloukal K; Schneeberger A; Berger M; Schmidt W; Koszik F; Kutil R; Cotten M; Wagner E; Buschle M; Maass G
J Immunol; 1995 Apr; 154(7):3406-19. PubMed ID: 7897222
[TBL] [Abstract][Full Text] [Related]
3. NK cell-mediated anti-tumor immune response to human prostate cancer cell, PC-3: immunogene therapy using a highly secretable form of interleukin-15 gene transfer.
Suzuki K; Nakazato H; Matsui H; Hasumi M; Shibata Y; Ito K; Fukabori Y; Kurokawa K; Yamanaka H
J Leukoc Biol; 2001 Apr; 69(4):531-7. PubMed ID: 11310838
[TBL] [Abstract][Full Text] [Related]
4. Early-appearing tumour-infiltrating natural killer cells play a crucial role in the generation of anti-tumour T lymphocytes.
Kurosawa S; Harada M; Matsuzaki G; Shinomiya Y; Terao H; Kobayashi N; Nomoto K
Immunology; 1995 Jun; 85(2):338-46. PubMed ID: 7642226
[TBL] [Abstract][Full Text] [Related]
5. Natural killer cells play a role in MHC class I in vivo induction in tumor cells that are MHC negative in vitro.
Kijima M; Saio M; Oyang GF; Suwa T; Miyauchi R; Kojima Y; Imai H; Nakagawa J; Nonaka K; Umemura N; Nishimura T; Takami T
Int J Oncol; 2005 Mar; 26(3):679-84. PubMed ID: 15703823
[TBL] [Abstract][Full Text] [Related]
6. Dissimilar anti-tumour reactions induced by tumour cells engineered with the interleukin-2 or interleukin-15 gene in nude mice.
Di Carlo E; Meazza R; Basso S; Rosso O; Comes A; Gaggero A; Musiani P; Santi L; Ferrini S
J Pathol; 2000 Jun; 191(2):193-201. PubMed ID: 10861581
[TBL] [Abstract][Full Text] [Related]
7. Impaired tumorigenicity of human pancreatic cancer cells retrovirally transduced with interleukin-12 or interleukin-15 gene.
Yoshida Y; Tasaki K; Miyauchi M; Narita M; Takenaga K; Yamamoto H; Yaaguchi T; Saisho H; Sakiyama S; Tagawa M
Cancer Gene Ther; 2000 Feb; 7(2):324-31. PubMed ID: 10770643
[TBL] [Abstract][Full Text] [Related]
8. Characterization and tumorigenicity of human neuroblastoma cells transfected with the IL-2 gene.
Corrias MV; Basso S; Meazza R; Musiani P; Santi L; Bocca P; Occhino M; Ferrini S; Pistoia V
Cancer Gene Ther; 1998; 5(1):38-44. PubMed ID: 9476965
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-2-secreting mouse fibroblasts transfected with genomic DNA from murine neoplasms induce tumor-specific immune responses that prolong the lives of tumor-bearing mice.
Sun T; Kim TS; Waltz MR; Cohen EP
Cancer Gene Ther; 1995 Sep; 2(3):183-90. PubMed ID: 8528961
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-2-secreting mouse fibroblasts transfected with genomic DNA from murine melanoma cells prolong the survival of mice with melanoma.
Kim TS; Cohen EP
Cancer Res; 1994 May; 54(10):2531-5. PubMed ID: 8168073
[TBL] [Abstract][Full Text] [Related]
11. Cationic lipid gene transfer of an IL-2 transgene leads to activation of natural killer cells in a SCID mouse human tumor xenograft.
Clark PR; Stopeck AT; Parker SE; Hersh EM
Cell Immunol; 2000 Sep; 204(2):96-104. PubMed ID: 11069717
[TBL] [Abstract][Full Text] [Related]
12. Effect of human natural killer cells on the metastatic growth of human melanoma xenografts in mice with severe combined immunodeficiency.
Hill LL; Perussia B; McCue PA; Korngold R
Cancer Res; 1994 Feb; 54(3):763-70. PubMed ID: 8306339
[TBL] [Abstract][Full Text] [Related]
13. Role of interleukin (IL)-2 and IL-15 in the tumour progression of a melanoma cell line MELP, derived from an IL-2 progressor patient.
Doucet C; Meazza R; Pottin-Clemenceau C; Scudeletti M; Brouty-Boye D; Ferrini S; Alileche A; Taoufik Y; Jasmin C; Azzarone B; Indiveri F
Melanoma Res; 1997 Aug; 7 Suppl 2():S7-17. PubMed ID: 9578412
[TBL] [Abstract][Full Text] [Related]
14. Vaccination with B16 melanoma cells expressing a secreted form of interleukin-1beta induces tumor growth inhibition and an enhanced immunity against the wild-type B16 tumor.
Björkdahl O; Dohlsten M; Sjögren HO
Cancer Gene Ther; 2000 Oct; 7(10):1365-74. PubMed ID: 11059695
[TBL] [Abstract][Full Text] [Related]
15. Neutralization of interleukin-2 retards the growth of mouse renal cancer.
Fukuhara H; Matsumoto A; Kitamura T; Takeuchi T
BJU Int; 2006 Jun; 97(6):1314-21. PubMed ID: 16686731
[TBL] [Abstract][Full Text] [Related]
16. Lack of correlation between natural killer activity and tumor growth control in nude mice with different immune defects.
Fodstad O; Hansen CT; Cannon GB; Statham CN; Lichtenstein GR; Boyd MR
Cancer Res; 1984 Oct; 44(10):4403-8. PubMed ID: 6467201
[TBL] [Abstract][Full Text] [Related]
17. Experimental gene therapy of cancer using tumor cells engineered to secrete interleukin-13.
Lebel-Binay S; Laguerre B; Quintin-Colonna F; Conjeaud H; Magazin M; Miloux B; Pecceu F; Caput D; Ferrara P; Fradelizi D
Eur J Immunol; 1995 Aug; 25(8):2340-8. PubMed ID: 7664796
[TBL] [Abstract][Full Text] [Related]
18. Local inhibition of natural killer cell activity promotes the progressive growth of intraocular tumors.
Apte RS; Mayhew E; Niederkorn JY
Invest Ophthalmol Vis Sci; 1997 May; 38(6):1277-82. PubMed ID: 9152248
[TBL] [Abstract][Full Text] [Related]
19. Impairment of natural killer functions by interleukin 6 increases lymphoblastoid cell tumorigenicity in athymic mice.
Tanner J; Tosato G
J Clin Invest; 1991 Jul; 88(1):239-47. PubMed ID: 1647416
[TBL] [Abstract][Full Text] [Related]
20. IFN-gamma-independent synergistic effects of IL-12 and IL-15 induce anti-tumor immune responses in syngeneic mice.
Comes A; Di Carlo E; Musiani P; Rosso O; Meazza R; Chiodoni C; Colombo MP; Ferrini S
Eur J Immunol; 2002 Jul; 32(7):1914-23. PubMed ID: 12115611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
